Journal article

Standardized Nomenclature for Modified Rankin Scale Global Disability Outcomes Consensus Recommendations From Stroke Therapy Academic Industry Roundtable XI

Jeffrey L Saver, Napasri Chaisinanunkul, Bruce C Campbell, James C Grotta, Michael D Hill, Pooja Khatri, Jaren Landen, Maarten G Lansberg, Chitra Venkatasubramanian, Gregory W Albers



The modified Rankin Scale (mRS), a 7-level, clinician-reported, measure of global disability, is the most widely employed outcome scale in acute stroke trials. The scale's original development preceded the advent of modern clinimetrics, but substantial subsequent work has been performed to enable the mRS to meet robust contemporary scale standards. Prior research and consensus recommendations have focused on modernizing 2 aspects of the mRS: operationalized assignment of scale scores and statistical analysis of scale distributions. Another important characteristic of the mRS still requiring elaboration and specification to contemporary clinimetric standards is the Naming of scale outcomes. R..

View full abstract


Funding Acknowledgements

Dr Saver is an employee of the University of California. Dr Saver and Dr Sidney Starkman created the Rankin Focused Assessment while University of California employee, and Dr Saver, Dr Starkman, and University of California, Regents have made the RFA freely and permanently available as a no-fee public resource under a Creative Commons, use-freely-with-attribution license. Dr Saver and Dr Sidney Starkman also created a written vignette rater certification program for the Rankin Focused Assessment while University of California employee. The written vignettes are an optional system for training and certifying raters in the use of the free RFA resource. The University of California, Regents, along with Dr Saver and Dr Starkman, hold a copyright for the written vignette rater certification system. Any revenues received under that copyright are used to support the training of Vascular Neurology Fellows at UCLA. Dr Landen is an employee of Biogen. Dr Hill reports grants from NoNO, Inc, grants from Medtronic, grants from Boehringer Ingelheim, and grants from Biogen outside the submitted work; in addition, Dr Hill has a patent to US Patent office Number: 62/086,077 issued and licensed; and owns stock in Pure Web Incorporated, a company that makes, among other products, medical imaging software, is a director of the Canadian Federation of Neurological Sciences, a not-for-profit group, is a director of the Canadian Stroke Consortium, a not-for-profit group, is a director of Circle NeuroVascular, Inc, and has received grant support from Alberta Innovates Health Solutions, CIHR, Heart & Stroke Foundation of Canada, National Institutes of Neurological Disorders and Stroke. Dr Khatri reports grants from Cerenovus, and consulting fees from Lumosa and Diamedica to her department, and she has received personal fees from Bayer for trial effort and from Basking Biosciences for consulting outside the submitted work. Dr Lansberg reports grants from NIH during the conduct of the study. Dr Albers reports personal fees and other from iSchemaView and personal fees from Genentech outside the submitted work. The other authors report no conflicts.